Lixoft becomes a wholly owned subsidiary of Simulations Plus on April, 2020. Lixoft is design software solutions based on scientific breakthroughs to reduce the cost and increase the success rate of new drug development. Learn More
Simulations Plus released version 10.0 of its flagship machine learning modeling platform, ADMET Predictor®, The new release is marketed as APX™ on September 2020. Read More
Shawn M. O’Connor appointed as Chief Executive Officer(CEO) effective from June 26, 2018. Learn More
Predictions of ionization constants performed by the S+pKa method implemented in ADMET Predictor™ software wins SAMPL6 pKa challenge on February 2018. Learn More
DILIsym becomes a wholly owned subsidiary of Simulations Plus. DILIsym is the global leader in the simulation of drug-induced liver injury (“DILI”). Learn More
Jill Fiedler-Kelly awarded with ISoP Fellowship for her professional excellence and superior impact in pharmacometrics, and for substantial volunteering work for ISoP on October, 2016. Learn More
Simulations Plus released version 1.0 of PKPlus™, its next-generation software for analysis of preclinical and clinical trial data. Learn More
Lixoft released version 1.0 of Simulx, an easy, efficient and flexible application for clinical trail simulations, on December 2014. Learn More
Simulations Plus announced that it has expanded its product portfolio with the release of version 1.0 of its MembranePlus™ simulation software on October 2014. Learn More
Cognigen became a wholly-owned subsidiary of Simulations Plus on September 2014. Learn More
Joel S. Owen and Jill Fiedler-Kelly published a textbook on “Introduction to Population Pharmacokinetic / Pharmacodynamic Analysis with Nonlinear Mixed Effects Models” on July 2014. Read More
Dr. Grasela was awarded the Gary Neil Prize for Innovation in Drug Development from the American Society for Clinical Pharmacology and Therapeutics(ASCPT). Learn More
DILIsym® Version 1A was released on January 2012. Learn More
Monolix® Version 1.0 was released on October 2011. Learn More
Simulations Plus has been named to the ninth annual Fortune Small Business FSB 100 list of the fastest-growing small public companies in America. Learn More
Simulations Plus released version 1.0 of DDDPlus™, a simulation of in vitro dissolution experiments for formulation scientists in the pharmaceutical industry on February 2005. Learn More
In 1999, Simulations Plus listed on the NASDAQ (American Stock Exchange) under the symbol SLP.
Simulations Plus released version 1.0 of ADMET Predictor™, formerly known as QMPRPlus™ on January 2005. Learn More
Simulations Plus releases its flagship PBPK modeling and simulation, GastroPlus®, in July 1998. Learn More
Simulations Plus incorporated in Lancaster, California in July 1996.